Anti-TfR/BACE1 bispecific antibodies cross the blood-brain barrier and reduce brain amyloid-beta levels in human TfR knock-in mice.

Evidence span

Anti-TfR/BACE1 bispecific antibodies cross the blood-brain barrier and reduce brain amyloid-beta levels in human TfR knock-in mice.

From Yu YJ et al. 2014, Sci Transl Med

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

source-reported model organism

Conditions

intravenous dosing of anti-TfR/BACE1 antibodies

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required